100
Participants
Start Date
June 30, 2011
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Trastuzumab, Docetaxel
"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
Trastuzumab, Docetaxel, Bevacizumab
"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
Trastuzumab+Docetaxel+NPLD
"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
Trastuzumab+Docetaxel+NPLD+Bevacizumab
"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
Med. Univ. Vienna; General Hospital Vienna, Vienna
Medical University Vienna, General Hospital, Vienna
State Hospital Vienna-Hietzing, Vienna
Hospital BHS Linz, Coop. Study Group, Linz
AKH Linz, Linz
Paracelsus Medical University Salzburg-Oncology, Coop. Group, Salzburg
Gynaegological Medical University Innsbruck, Innsbruck
District Hospital Kufstein, Kufstein
State Hospital Feldkirch, Coop. Group, Feldkirch
Medical University of Graz-Oncology; Coop. Group, Graz
State Hospital Leoben, Leoben
Collaborators (1)
Hoffmann-La Roche
INDUSTRY
Cephalon
INDUSTRY
Austrian Breast & Colorectal Cancer Study Group
NETWORK